Amlexanox

Amlexanox is a small-molecule anti-inflammatory and anti-allergic drug, chemically an aminopyridine derivative, first introduced decades ago in Japan. In clinical use it is best known as a topical 5 percent oral paste or mucoadhesive tablet for recurrent aphthous stomatitis (canker sores), and in some markets it has also been used for allergic rhinitis and asthma ^[3][5]. Its original described action was inhibition of inflammatory mediator release from mast cells and other leukocytes.

Interest in amlexanox expanded dramatically after 2013, when researchers reported that it is a selective inhibitor of two noncanonical IkB kinases, IKKe (IKK-epsilon) and TANK-binding kinase 1 (TBK1), which become elevated in obesity and help lock in energy storage ^[1]. In diet-induced obese mice, amlexanox raised energy expenditure, produced weight loss, improved insulin sensitivity, and reduced hepatic steatosis ^[1]. A subsequent proof-of-concept randomized, double-blind, placebo-controlled study in 42 obese patients with type 2 diabetes and nonalcoholic fatty liver disease found a statistically significant reduction in hemoglobin A1c and fructosamine, with a distinct responder subgroup that also improved insulin sensitivity ^[2]. Beyond metabolism, amlexanox has been explored as a Wnt/beta-catenin activator promoting lung epithelial repair in emphysema models ^[6] and as a suppressor of neuroinflammatory signaling in microglia ^[7].

Regulatory status varies by indication and region; amlexanox is an approved medicine for aphthous ulcers in several countries but is not approved for obesity, diabetes, or any metabolic indication, where it remains investigational ^[2]. It is supplied as oral paste and mucoadhesive dosage forms clinically, and as a research powder for laboratory and metabolic studies.

Amlexanox is an anti-inflammatory drug approved in some markets as an oral paste for aphthous (mouth) ulcers and studied experimentally as an IKK-epsilon/TBK1 inhibitor for metabolic disease. Topical use can cause local stinging, irritation, or contact dermatitis; systemic use for metabolic indications is investigational, with limited long-term human safety data and reported effects such as nausea and gastrointestinal upset.

Amlexanox was developed in Japan by Takeda as an anti-allergic and anti-inflammatory agent, and it reached the United States market in 1996 as Aphthasol, a topical oral paste approved for the treatment of aphthous ulcers, or canker sores. For much of its history it was a modest niche product used simply to speed the healing of mouth ulcers. Interest surged in 2013 when a team led by Alan Saltiel reported in Nature Medicine that amlexanox inhibits the noncanonical inflammatory kinases TBK1 and IKK-epsilon, and that this action reversed obesity, insulin resistance, and fatty liver in mice. That discovery repositioned a decades-old ulcer drug as a leading candidate in metabolic drug repurposing, and a proof-of-concept trial in patients with type 2 diabetes followed in 2017.

Amlexanox enjoys an unusual dual reputation; it is a quietly dependable topical remedy for painful mouth ulcers and, at the same time, one of the more talked-about repurposing stories in metabolic research. Scientists find it compelling because it links chronic low-grade inflammation directly to energy storage through two specific kinases, offering a clean mechanistic handle on obesity and diabetes. The human data remain early and honest observers note that only a subset of patients, identifiable by a distinct inflammatory signature in their fat, responded strongly. Still, the fact that a well-tolerated, long-approved drug can nudge glucose control and thermogenesis keeps it a favorite subject of ongoing investigation.